Key result
Drug-coated balloons provide effective stent-free CAD alternatives when guided by specific plaque morphologies.
Why the study?
Advances in DCB technology have introduced SCBs alongside standard PCBs, prompting the need to review their mechanisms, impact across different plaque morphologies, and clinical implications.
How do paclitaxel-coated and sirolimus-coated balloons compare in efficacy across different coronary plaque morphologies, in-stent restenosis, and small vessel disease?
How do paclitaxel-coated and sirolimus-coated balloons compare in efficacy across different coronary plaque morphologies, in-stent restenosis, and small vessel disease?
This narrative review highlights that sirolimus-coated balloons are a viable, non-inferior alternative to paclitaxel-coated balloons, with selection potentially guided by specific plaque morphologies such as calcification or inflammation.
The evolution of percutaneous coronary intervention (PCI) has led to significant advances in drug-coated balloon (DCB) technology, offering a stent-free alternative for treating coronary artery disease. While paclitaxel-coated balloons (PCBs) have been the standard, sirolimus-coated balloons (SCBs) are emerging as a viable alternative with distinct pharmacokinetic and clinical benefits. This review explores the mechanisms of action of paclitaxel and sirolimus, their impact on different plaque morphologies, and the clinical implications of DCB selection. Paclitaxel facilitates positive vascular remodeling and is particularly effective in fibrotic and lipid-rich plaques, but its poor penetration in calcified lesions remains a limitation. Sirolimus, with its homogeneous tissue distribution and anti-inflammatory properties, is better suited for unstable, lipid-rich, and inflammatory plaques, where it promotes plaque stabilization. Recent randomized trials and meta-analyses have compared SCBs vs. PCBs in both de novo lesions and in-stent restenosis, showing non-inferior outcomes. Additionally, DCBs demonstrate comparable efficacy to DES in small vessel disease, reducing the need for permanent metallic scaffolds. This review summarizes the current evidence on DCB selection based on plaque characteristics and highlights areas for further investigation in personalized PCI strategies. Given the narrative review design, the authors conducted a comprehensive literature search using databases such as PubMed and MEDLINE. Keywords included "drug-coated balloon", "paclitaxel-coated balloon", "sirolimus-coated balloon", "in-stent restenosis", and "plaque morphology". Studies were selected based on relevance, including randomized controlled trials, registries, and meta-analyses. No formal inclusion/exclusion criteria or systematic screening were applied due to the nature of narrative synthesis.
No takes yet. Share an insight, caveat, or question.
Gherasie et al. (2025) conducted a review in coronary artery disease. Drug-coated balloons (paclitaxel and sirolimus) was evaluated. Drug-coated balloons, including paclitaxel and sirolimus variants, provide effective stent-free alternatives for coronary artery disease, with selection guided by specific plaque morphologies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: